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’INTRODUCTION
A major component of the adaptive immune response to
infectionisthegenerationofprotectiveandlong-lastinghumoral
immunity, but factors governing selection of the particular antigens
recognized are unclear.
1,2 It is not uncommon for viruses encoding
a small number of proteins to generate antibodies against each
encoded protein. But for infectious agents containing hundreds
or thousands of proteins only a subset of the proteome is
recognized and little is known about the extent or the
characterisitics of this subset of antigens. Methods for making a
complete empirical accounting of the immunoproteome have
limitations, particularly when the genome of the organism is
large. Here we describe a B. melitensis proteome microarray that
enables this problem to be directly addressed by applying an
unbiased systems biology approach to identify immunodominant
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ABSTRACT: A complete understanding of the factors that determine
selectionofantigensrecognizedbythehumoralimmuneresponsefollowing
infectious agent challenge is lacking. Here we illustrate a systems biology
approachtoidentifytheantibodysignatureassociatedwithBrucellamelitensis
(Bm) infection in humans and predict proteomic features of serodiagnostic
antigens. By taking advantage of a full proteome microarray expressing
previously cloned 1406 and newly cloned 1640 Bm genes, we were able to
identify122immunodominantantigensand33serodiagnosticantigens.The
reactive antigens were then classiﬁed according to annotated functional
features (COGs), computationally predicted features (e.g., subcellular
localization, physical properties), and protein expression estimated by mass
spectrometry (MS). Enrichment analyses indicated that membrane associa-
tionandsecretionweresigniﬁcantenrichingfeaturesofthereactiveantigens,
aswereproteinspredictedtohaveasignalpeptide,asingletransmembranedomain,andoutermembraneorperiplasmiclocation.These
featuresaccountedfor67%oftheserodiagnosticantigens.Anoverlayoftheseroreactiveantigensetwithproteomicdatasetsgenerated
by MS identiﬁed an additional 24%, suggesting that protein expression in bacteria is an additional determinant in the induction of
Brucella-speciﬁcantibodies.Thisanalysisindicatesthatone-thirdoftheproteomecontainsenrichingfeaturesthataccountfor91%ofthe
antigensrecognized,andafterB. melitensis infectiontheimmunesystemdevelopssigniﬁcantantibodytitersagainst10%oftheproteins
withtheseenrichingfeatures.Thissystemsbiologyapproachprovidesanempiricalbasisforunderstandingthebreadthandspeciﬁcityof
the immune response to B. melitensis and a new framework for comparing the humoral responses against other microorganisms.
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and serodiagnostic antigens and to classify the reactive antigens
based on functional and physical properties.
Proteinmicroarrayscanbeusedwithrelativeeasetoprobethe
entireproteomeofdiﬀerentinfectiousmicroorganismsincluding
bacteria, viruses and parasites.
3 13 This approach permits assessing
the repertoire of antibodies produced in response to infections or
vaccinations from large collections of individual patient sera, and
canbeusedtoperformlarge-scalesero-epidemiologicalandsero-
surveillance analyses not possible with other technologies, while
consuming small quantities (<2 μL) of each serum sample.
Probinglargenumbersofpatientspecimensempowersthestatistical
tests resulting in more reliable conclusions while correcting for
false discovery required formultiplecomparisontestinginherent
inmicroarrayanalysis.
3,5,7,9Moreover,microarrayscandisplayall
proteinsofaninfectiousagentandmayallowforidentiﬁcationof
novel antigens, otherwise undetectable by methods like 2-D gels
that are highly biased by microbial protein expression patterns.
Brucellosis is a worldwide zoonosis caused by bacteria of the
genusBrucella.Brucellamelitensis,themostvirulentspeciesinfecting
humans, also infects goats, sheep and cattle,
14 16 in Central and
South America, the Middle East, East Asia, and some southern
Europeancountries.
17,18Consumptionofanimalproducts,direct
animal contact and inhalation of aerosolized bacteria in the
laboratory setting (indicating the potential for air-borne spread
via a bioterrorism-type attack) are well-recognized routes of
infection. The current knowledge of protein antigens recognized
by humans and reservoir animals is based on limited numbers of
studies on Brucella melitensis and Brucella abortus.
19 31
We recently constructed a pilot proteome array consisting of
1406 B. melitensis proteins and observed marked diﬀerences in
immune responses between humans and goats.
5 Here we have
expanded our previous study to the full proteome microarray
consisting of 3046 B. melitensis proteins, by including expression
of newly cloned 1640 Bm genes. In addition to developing a
betterclassiﬁercapableofpredictingdiseasebasedonserological
response, more importantly, this study allows an estimate of the
extent of immune reactivity against the whole proteome, and
prediction of proteomic features that may dictate immune recogni-
tion for other yet uncharacterized gram-negative bacteria.
’MATERIALS AND METHODS
Ethics Statement
Human sera were obtained from patients enrolled in a prospec-
tive clinical study of brucellosis in Lima, Peru. The human subjects
partofthestudywasapprovedbytheHumansResearchProtections
CommitteeoftheUniversityofCaliforniaSanDiego,theComitede
  Etica of Universidad Peruana Cayetano Heredia, Lima, Peru and
theComitede  EticaofAsociaci  onBen  eﬁcaPRISMA,Lima,Peru,
all of whom have maintained federal wide assurances with the
United States Department of Health and Human Services. All
patients provided written informed consent prior to enrollment
inthestudy,andsignedconsentformshavebeenstoredinlocked
ﬁles in study oﬃces at UPCH and AB PRISMA, Lima, Peru.
Human Serum Samples
Human sera were obtained from patients in Lima, Peru. All
patients in this studywere infected with B. melitensis biovar 1.
Forty- two patients were conﬁrmed to have acute brucellosis by
positive culture, positive Rose Bengal test and by tube agglutina-
tion tests titers g1/160. Eighteen patients presenting with
brucellosis-compatible syndromes were culture negative and Rose
Bengal positive, and treated according to standard antibiotic
therapy within 2 days of serum sampling. Additional control
patient samples included 13 sera from Rose Bengal-negative
patients, 44 samples from ambulatory healthy controls from
north Lima where brucellosis occasionally aﬀects patients, and
sera from humans in the U.S. where brucellosis is not found.
Brucella melitensis Lipopolysaccharide Purification
Approximately 10 g of autoclaved pellet of B. melitensis 16 M
were used to isolate LPS using the hot phenol-water method.
32
The puriﬁed LPS was treated with RNase, DNase and Protei-
nase-K, and the hot phenol-water treament was repeated. B.
melitensis LPS obtained from both upper phenol saturated aqu-
eous layer (aqueous phase) and lower water saturated phenol
layer (phenol phase) were pooled. LPS from E. coli 055:B5 was
purchased from Sigma Chemicals (St. Louis, MO). The LPS
from E. coli 055:B5 and B. melitensis 16 M were analyzed on a
gradient 4 12% Tris-Glycine sodium dodecyl sulfate (SDS)
polyacrylamide gel (Invitrogen Corp., Carlsbad, CA) under redu-
cing conditions. The presence of LPS in the gels was detected
with a periodic acid silver stain
33 and protein using Coomassie
blue stain. B. melitensis LPS was quantiﬁed using a colorimetric
assay to measure 2-keto-3-deoxyoctonate (KDO) concentration.
34
E. coli055: B5 LPS (Sigma, St. Louis, MO) wasusedas standard.
Microarray Fabrication,Probing and Immunostrips Probing
All ORFs from Brucella melitensis 16 M genomic DNA were
identiﬁed using GenBank NC_003317 and NC_003318, and
1640 ORFs that were absent from pilot chip were ampliﬁed and
cloned using ahigh-throughput PCR and recombination cloning
method described previously.
5 Microarrays and immunostrips
were fabricated and probed as described before.
5 Plasmids were
expressed at 24  C for 16 h in in vitro transcription/translation
E. coli reactions (Expressway Maxi kits from Invitrogen), accord-
ing to the manufacturer’s instructions. For microarrays, 10 μLo f
reaction was mixed with 3.3 μL 0.2% Tween 20 to give a ﬁnal
concentration of 0.05% Tween 20, and printed onto nitrocellu-
lose coated glass FAST slides (Whatman) using an Omni Grid
100microarray printer (Genomic Solutions). Forimmunostrips,
B. melitensis LPS was printed at 0.01 mg/mL. All antigens were
printed on Optitran BA-S 85 0.45 μm Nitrocellulose membrane
(Whatman)usingBioJetdispenser(BioDot)at1μL/cm,andcut
into3mmstrips.Humanserasamplesweredilutedto1:200with
10 mg/mL E. coli lysate (Mclab). Microarray slides were in-
cubated in biotin-conjugated secondary antibody (Jackson Im-
munoResearch) diluted 1/200 in blocking buﬀer, and detected
by incubation with streptavidin-conjugated SureLight P-3 (Columbia
Biosciences). The slides were washed and air-dried by brief
centrifugation. Microarray slides were scanned and analyzed
usingaPerkin-ElmerScanArray ExpressHTmicroarray scanner.
Intensities were quantiﬁed using QuantArray software. All signal
intensities were corrected for spot-speciﬁc background. For
immunostrips probing, human sera were diluted to 1/200 in
5% BSA solution containing 20% E. coli lysate (McLab).
Strips were then incubated in alkaline phosphatase conjugated
donkey antihuman immunoglobulin (anti-IgG, Fcγ fragment-
speciﬁc, Jackson ImmunoResearch) secondary antibody, diluted
to 1/2000, and reactive bands were visualized by incubating with
1-step Nitro-Blue Tetrazolium Chloride/5-Bromo-4-Chloro-30-
Indolyphosphate p-Toluidine Salt (NBT/BCIP) developing
buﬀer (Thermo Fisher Scientiﬁc). Immunostrips were scanned
with Hewlett-Packard document scanner, and were quantiﬁed
using Image J software.4815 dx.doi.org/10.1021/pr200619r |J. Proteome Res. 2011, 10, 4813–4824
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MassSpectrometryDataSetfromPathogenPortalWebSite
The mass spectrometry data set “characterization of host and
pathogen proteins aﬀected by Brucella abortus infection” was
from Caprion Proteomics studies of B abortus, downloadable
from pathogen portal web site hosted by proteomics resource
center at http://www.pathogenportal.org/portal/portal/Path-
Port/Home. Samples were processed for “intact bacteria” or
“cellenvelope”preparationsfromexponentiallygrowingbacteria
according to the Caprion protocol 24401 and 24302, as described
before.
23,35 Brieﬂy, to process intact bacteria for MS analysis,
50 μL aliquots of 20 μg protein samples were denatured in
50 mM ammonium bicarbonate (Sigma-Aldrich, St. Louis, MO)
containing 8 M urea. After sonication, samples were centrifuged
at 2000  g for 1 min and a 950 μL cold ( 20  C) chloroform/
methanol solution (2:1 v/v) were added. Samples were vortex
mixed and incubated at  20  C for 2 h. Subsequently, 100 μL
cold ( 20  C) methanol was added and samples were clariﬁed
by centrifugation at 21000  g for 10 min at 4  C. The super-
natants were dried under vacuum, resuspended in 100 mM
ammonium bicarbonate containing 8 M urea and 1% (w/v) of
acid-labile surfactant (ALS; Waters, Milford, MA) and sonicated
for10min.Aftercentrifugationfor20sat2000 g,sampleswere
incubated for1hatambienttemperature.Avolumeof450μLof
100 mM ammonium bicarbonate containing 5% (v/v) of aceto-
nitrile was added. Lys-C (Wako, Richmond, VA) was added to
yielda1:50enzymetoproteinratio.Thesampleswereincubated
for 3 h at 37  C. Trypsin (Promega, Madison, WI) was then
added at a 1:50 enzyme to protein ratio and samples were
incubated for an additional 16 h. Following proteolysis, TCEP
(Pierce, Rockford, IL) was added to a ﬁnal concentration of
10 mM and samples were incubated for 30 min at ambient
temperature and then lyophilized. To cleave the acid labile surfac-
tant, samples were incubated for 30 min at ambient temperature
in 100 μL of 1 N HCl and 100 μL of water were added into each
sample with subsequent incubation for another half hour at
ambient temperature. To process cell envelope for MS analysis,
supernatants of exponentially growing B. abortus strains were
clariﬁed, centrifuged at 100000  g for 6 h at 4  C, pellets
resuspendedindoubledistilledwater.Thesamplewassonicated,
and 50 mM ammonium bicarbonate containing 2% acid-labile
surfactant and 8 M urea were added. The sample was vortex
mixed for 1 h. A sample of 50 μL of the OM suspension was added
to a ﬁnal volume of 1 mL of a chloroform/methanol solution
(2:1v/v).Thesamplewasvortexmixedandincubatedat 20 C
for 2 h. Subsequently, 100 μL of cold methanol ( 20  C) was
added,andthesamplewasclearedbycentrifugationfor10minat
21000  g. The supernatant was dried under vacuum and
resuspended in 4 M urea; 50 mM ammonium bicarbonate pH
8.0. Lys-C was added at a 1:50 protein ratio. The samples were
then diluted 4:1 with 50 mM ammonium bicarbonate buﬀer pH
8.0,andtrypsinwasaddedata1:25proteinratioforanadditional
16 h. Following proteolysis, the samples were distributed into
96-well plates for mass spectrometry analysis.
Peptidedigestswereanalyzedbyliquidchromatographycoupled
tomassspectrometry(LC-MS) asdescribed.
23,35,36 The LC MS
system consisted of a CapLC (Waters, Milford, MA) with a
cooled autosampler and a QTOF Ultima (Waters, Milford, MA)
controlled by MassLynx version 4.0 software. The peptide con-
centrationswerenormalizedandthesampleswereinjectedintoa
reversed-phase column (Jupiter C18, Phenomenex, Torrance,
CA) for HPLC separation. Protein identiﬁcation was done by
submitting LC MS spectra to Mascot software (MatrixScience,
Boston, MA) for searching against the National Center for
Biotechnology Information protein database (NCBI). The para-
meters used for Mascot search and protein homology cluster-
ing were previously detailed.
23,35 Numbers of diﬀerent peptides
for each identiﬁed protein were counted and listed in Table S4
(Supporting Information).
Data Analysis
Data analysis was performed using the R (http://www.
r-project.org) and SAS (http://www.sas.com/) statistical software.
It has been noted in literature that data derived from microarray
platforms is heteroskedatic.
37 39 To stabilize the variance,
40,41
the vsn normalization method implemented as part of the Biocon-
ductor suite (www.bioconductor.org) was applied to the quanti-
ﬁed array intensities. In addition to removing heteroskedacity,
this procedure corrects for nonspeciﬁc noise eﬀects by ﬁnding
maximum likelihood shifting and scaling parameters for each
arraysuchthatcontrolprobevarianceisminimized.Thiscalibration
has been shown to be eﬀective on a number of platforms.
42
Diﬀerentially reactive proteins between groups were deter-
mined using a Bayes regularized t test adapted from Cyber-T for
protein arrays,
37,43 which has been shown to be more eﬀective
than other diﬀerential expression techniques.
44 To account for
multiple comparison conditions, the Benjamini and Hochberg
(BH)methodwasusedtocontrolthefalsediscoveryrate.
45After
Benjamini and Hochberg correction, p-value smaller than 0.05
was considered signiﬁcant, and the corresponding protein was
considered diﬀerentially reactive and serodiagnostic. Multiplex
classiﬁers were constructed using linear and nonlinear Support
Vector Machines (SVMs) using the “e1071” R package. Plots of
receiver operating characteristic (ROC) curves were made with
the “ROCR” R package. Sensitivity speciﬁcity and Area Under
the Curve (AUC) were determined from the resulting ROC
curves. Principle Component Analysis (PCA) to visually reduce
and summarize signal intensity variance among the subjects was
conducted in JMP software (www.JMP.com).
Hierarchical clustering was used to group sera samples into
subsets, such that those within each cluster (subset) are more
closely related to one another than samples assigned to other
clusters. Clustering is based on the degree of similarity between
theproteinintensityforeachindividual.MeVv4.6(TM4Microarray
SoftwareSuite,www.tm4.org)wasusedtoperformtheclustering
analysis.
The following programs were utilized for computational pre-
diction. TMHMM v2.0 was utilized for transmembrane domains
prediction
46(http://www.cbs.dtu.dk/services/TMHMM/),SignalP
v3.0 for signal peptide prediction
47 (http://www.cbs.dtu.dk/
services/SignalP/), PSORTb v3.0. software for cellular location
prediction
48 (http://www.psort.org/psortb/). PI/MW tool
from Swiss Institute of Bioinformatics was used to determine
isolectric point (http://ca.expasy.org/tools/pi_tool.html). P value
for enrichment statistical analysis was calculated using Fisher’s exact
test in the R environment.
’RESULTS
Gene Amplification, Cloning and Protein Expression
The 3198 predicted ORFs of B. melitensis (Bm) 16 M were
subjected to ampliﬁcation from genomic DNA, and 1406 ORFs
were cloned and printed on pilot chip.
5 In this study, another
1640 ORFs were successfully cloned using our high throughput
recombination method. About one-fourth of the cloned genes4816 dx.doi.org/10.1021/pr200619r |J. Proteome Res. 2011, 10, 4813–4824
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were sequenced and >99% of sequenced clones had the correct
sequence. All 3046 Bm ORFs cloned in pXT7 vector (>95% of
proteome) were expressed under T7 promoter in the E. coli in
vitro transcription/translation system, and printed on microar-
rays. Over 98% of protein spots were conﬁrmed positive for
expression (Figure S1A, Supporting Information).
Human Antibody Profile
Bm protein arrays were probed with sera from acute brucel-
losis patients in Lima, Peru obtained within 1 3 weeks of the
onset of symptoms, and sera from Bm culture-positive humans
(Figure S1B, Supporting Information) showed robust reactivity
against a collection of antigens compared to unexposed indivi-
duals. Among the 3046 antigens tested, 1464 antigens reacted
with at least one culture positive individual, accounting for 48%
of the proteome (Figure 1). Within this immunoproteome, 122
protein antigens were deﬁned “serodominant”, with mean re-
activity greater than the mean of the no DNA controls plus 2.5
standarddeviationsamongculturepositiveindividuals(Figure 2,
Figure S2 and Table S1, Supporting Information). Of these, 33
protein antigens were serodiagnostic, and were signiﬁcantly
diﬀerentiallyreactive betweenna€ ive and culture positive patients
from Peru (Benjamini and Hochberg adjusted Cyber-T p-value
<0.05). Most of these antigens also reacted strongly with sera
from brucellosis cases that were culture negative but positive for
theRoseBengaldiagnostictest.Anunbiasedhierarchicalcluster-
inganalysissegregatedmostoftheindividualspecimensintotwo
groups,withafewinfectedcaseswithweakreactivitysporadically
clustered among samples diagnosed as uninfected (Figure S2,
Supporting Information). Peruvian na€ ive samples exhibited very
lowresponsestothiscollectionofantigens.Wealsoidentiﬁed90
cross-reactive antigens that reacted similarly among all human
Figure 2. Discovery of new human serodiagnostic antigens by probing the full B. melitensis proteome arrays with a collection of B. melitensis Peruvian
na€ ive and culture positive human sera. The mean sera reactivity of the 3046 antigens was compared between the culture positive and Peruvian naive
groups. Antigens with Benjamini Hochberg corrected p-value lessthan 0.05 (serodiagnostic) are organized to the left and cross-reactive (BH_p> 0.05)
antigens to the right. Shown are the 33 serodiagnostic protein antigens, Bm LPS, and a subset of cross-reactive antigens.
Figure 1. Reactivity of the Immunoproteome. Each bar represents one of the 3046 proteins of B.melitensis. The bar height reﬂect the number of sera
reactive to each protein. Nonreactive proteins account for approximately 52% of the proteome. The raised bars of any color represent 1464 reactive
proteins,whichdeﬁnetheimmunoproteome(approximately48%oftheproteome).Thereare538antigensreactivein1sample,648antigensreactivein
2 5samples,143antigensreactivein6 9samplesand135antigensreactivein10 42samples.BMEI0536andBMEI1079reactedinall42Bmculture
positive samples. All serodiagnostic antigens except BMEI0503 reacted in 10 42 samples; BMEI0503 reacted in 9 samples.4817 dx.doi.org/10.1021/pr200619r |J. Proteome Res. 2011, 10, 4813–4824
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samples,whetherfromna€ iveindividualsorindividualsdiagnosed
to be infected.
Classifier of Serodiagnostic Antigens
We performed unsupervised principal component analysis
and showed that the 33 serodiagnostic antigens clearly separated
the Peruvian naive from culture positive groups (Figure 3A). To
furtherdeterminetheaccuracyofdistinguishingbrucellosiscases
from controls, cross-validation receiver operating characteristic
(ROC) curves and area under the curve (AUC) boxplots were
generated (Figure 3). The serodiagnostic antigens were ranked
by decreasing single antigen AUC. The top four ORFs, BMEI0536
(bp26), BMEI0805 (hypothetical protein), BMEI1330 (protease
Do), and BMEI 1890 (transporter), as wells as Bm LPS, all have
anindividualantigenAUCgreater than0.90(TableS1,Support-
ing Information). Three of the antigens were identiﬁed pre-
viously on microarrays.
5 Antigen bp26 (BMEI0536; AUC 0.991;
BHp-value<1 10
 16)gavethebestsingleantigendiscrimination
with95%sensitivityandspeciﬁcityrate.Weusedkernelmethods
and support vector machines
43,49 to build linear and nonlinear
classiﬁers.Variabilityandmeanvalueofaccuracyfromthismodel
has been shown in the AUC boxplot. The top 5 antigens all
produced sensitivity and speciﬁcity over 96% (Figure 3C). With
the top 3 antigens, this classiﬁer yielded a highest sensitivity
and speciﬁcity rate of 98.6 and 98.6%, respectively. Altogether
33 protein antigens plus LPS produced sensitivity and speciﬁcity
over 93%.
Validation of Serodiagnostic Accuracy with Immunostrips
Eighteen serodiagnostic proteins and Bm LPS were printed
ontonitrocellulosemembranesusingaBioDotjetdispenser.The
membrane was then cut into 3 mm strips. The individual strips
were probed with 31 diﬀerent randomly selected culture positive
sera and 31 Peruvian naive sera. Brucellosis patients reacted
strongly against the serodiagnostic antigens with variable signal
intensities among the patients. Na€ ive samples showed much
lower reactivity against these serodiagnostic antigens (Figure 4A).
The ROC curve (Figure 4B) shows that this immunostrip test
Figure 3. Statistical presentation of principal component analysis and multiple antigens AUC. (A) Unsupervised principal component analysis of the
signal intensity for samples from Peruvian naives and culture positive groups revealed that these two groups could be segregated on the basis of 33
selected serodianosis protein antigens and2 Bm LPS (at 0.1 mg/mL or 0.01 mg/mL). Theserodiagnostic antigens were ranked by single antigenAUC.
(B)Cross-validationAUCboxplotwithvarianceandmeanvalueand(C)cross-validationROCgraphsshowclassiﬁerswithincreasingnumberofhuman
serodiagnostic antigens. With the top 3 antigens, this classiﬁer yielded a highest sensitivity and speciﬁcity rate of 98.6% and 98.6%, respectively. All 33
antigens plus Bm LPS also produced sensitivity and speciﬁcity over 93%.
Figure 4. Immunostrips probing. (A) Eineteen serodiagnostic antigens and Bm LPS at 0.01 mg/mL were printed onto nitrocellulose membrane in
adjacent stripes using a BioDot jet dispenser as described in Materials and Methods. Strips were probed with culture positive or Peruvian naive sera
diluted 1/200 followed by alkaline phosphatase conjugated secondary antibody and enzyme substrate. Weak reactivity in the na€ ive healthy controls can
be distinguished from the strong reactivity in the infected group. (B) Cross-validation ROC curve was generated and sensitivity and speciﬁcity of
immunostrips test is 96% and 96%, respectively.4818 dx.doi.org/10.1021/pr200619r |J. Proteome Res. 2011, 10, 4813–4824
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yielded a high AUC of 0.97, with sensitivity rate of 96.7% and
speciﬁcity rate of 96.7%.
Comparing Blood Culture and Serological Testing by
Agglutination
Serological tests are routinely used to diagnose brucellosis.
While the qualitative agglutination test (Rose Bengal) is ∼90%
sensitivefor screening for acute/subacutebrucellosis,
50,51quantitative
agglutination testing (e.g., tube agglutination test (TAT)) with
titer typically greater than 1/160 used as a more precise diagnostic
criterion, can also be used to diagnose relapse. Often blood
cultures are negative at the time of initialpresentation or relapse,
possibly because of low levels of bacteremia or antecedent use of
antibiotics.Withoutbeingabletoascertainwhethertheseraused
in this study were obtained from patients who might have taken
antibiotics prior to blood cultures, we queried our data set to
Figure 5. Overview of an enrichment analysis of Bm proteome classiﬁed with COGs and computational predictions categories. (A) Overview of Bm
proteome classiﬁed with a total of 3291 COGs. The size of each slice represents the number of proteins assigned to each COG category. Proteins
classiﬁedwithCOGs-U,M,N,Ocategoriesaresigniﬁcantlyoverrepresentedinserodominantantigensandshowninextractedred.COG-Kproteinsare
signiﬁcantly underrepresented in serodominant antigens are shownin extracted black. COGcategories with <5 proteins were not included in the ﬁgure
(COGs-B, W). (B) Computational predictions for the Bm proteome are shown. Signiﬁcant over- and under-representations are shown in extracted red
or black, respectively. Numbersofserodominant antigens withinthese categories/number oftotal proteinswithin these categories are inparentheses in
the legend. Results of the complete COG analysis and computational predictions are in Table S3 (Supporting Information). (C) Correlation between
enrichment fold and peptide numbers detected by Mass Spectrometry. As peptide numbers for serdiagnostic antigens increase, enrichment fold for
serodiagnostic antigens also increases. In contrast, enrichment fold for cross-reactive antigens decreases as peptide numbers for cross-reactive antigens
increase.4819 dx.doi.org/10.1021/pr200619r |J. Proteome Res. 2011, 10, 4813–4824
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determinewhetherserafrombloodculture-positive,RoseBengal
positive brucellosis patients (gold standard diagnosis) vs blood
culture-negative, Rose Bengal positive (TAT not done) subjects
(presumptive positive, unconﬁrmed) recognized diﬀerent pro-
teins on the protein microarrays. Sera from blood culture-negative,
Rose Bengal positive subjects reacted with 10 B. melitensis
antigens much more strongly than blood culture-positive, Rose
Bengalpositiveindividuals(FigureS3,Supporting Information).
This unique set of 10 antigens was distinct from the 33 antigens
that distinguish culture positive cases from Peruvian na€ ives.
(Table S2, Supporting Information). These results indicate that
protein microarray analysis was able to delineate distinct anti-
body proﬁles in blood culture positive and negative patients,
which has the potential to identify antigens capable of diﬀer-
entiating active acute/subacute brucellosis from previously ex-
posed patients. These ﬁndings may suggest novel biological
interactions between bacteria and host that need to be further
explored because culture negativity/Rose Bengal seropositivity
might be associated with some biological diﬀerence between
human hosts, perhaps an immune response that might lower
bacterial loads to levels diﬃcult to culture from blood. Alterna-
tively, it is possible that antibiotic use might lead to an altered
host immune response to killed bacteria that no longer would
subvert the host immune responses (typical of intracellular
pathogens such as Brucella).
52 54
Enrichment Analysis
To better understand the determinants of antigenicity in
bacteria, we performed a functional enrichment analysis of the
serodominant and serodiagnostic antigens identiﬁed in this
study. Bm proteins are annotated with NCBI Clustered Ortho-
logous Group (COG) functional category. A total of 543 proteins
are unassociated withCOGs,and39 proteins are associated with
COGsbuthavenotbeenassignedtoacategory,shownas“Other
COGs”.SomeproteinshavemultipleCOGassignmentssothere
are 3,291 COGs in total for 3046 proteins on chip.
Proteins with predicted COG- U function, involved in intra-
cellular traﬃcking and secretion, were 6.2- fold enriched in
serodiagnostic antigens and 4.3- fold enriched in serodominant
antigens. The enrichment was signiﬁcant with p value <0.05.
Proteins in the COG-M category, cell envelope biogenesis and
outer membrane, were 2-foldenrichedinserodominant antigens
(p-value 0.01). Proteins in COG-N category, cell motility and
secretion, were 3.5-fold enriched in serodominant antigens (p =
0.027). ProteinswithpredictedCOG-Ofunction,posttranslational
modiﬁcation, protein turnover, chaperones, were also signiﬁcantly
enriched at 3.0-fold in serodominant antigens. There was only 1
serodominant antigen out of 176 COG-K category proteins,
predicted to be involved in transcription and identiﬁed as sero-
dominant, which was 0.1- fold enrichment and signiﬁcantly
underrepresented with p value of 0.014 (Figure 5A, Table S3A,
Supporting Information).
We also looked at enrichment of antigens using computation-
ally predicted features. As shown in Figure 5B and Table S3B
(Supporting Information), proteins with 1 transmembrane do-
mainweresigniﬁcantlyenrichedinserodominant,serodiagnostic
and cross-reactive antigens groups, with enrichment fold at 4.3,
5.0, and 4.0, respectively. Proteins lacking transmembrane domains
were signiﬁcantly underrepresented. Interestingly, proteins with
more than 1 transmembrane domain were also signiﬁcantly under-
represented among the serodominant and cross-reactive anti-
gens. Proteins with predicted signal peptides (SignalP score > 0.7)
weresigniﬁcantlyenrichedinallthreegroupsatarangeof2.8-to
3.6-fold. Conversely, proteins without signal peptides (SignalP
score < 0.7) were signiﬁcantly underrepresented. pSortb pre-
dicted 4 serodiagnostic and 5 serodominant outermembrane
antigens, resulting in 11.5-and 3.9-fold enrichment, respectively.
pSortb periplasmic proteins were also signiﬁcantly enriched,
from 3.1- to 4.2-fold. However, pSortb cytoplasmic proteins
were 0.5- to 0.7-fold underrepresented in serodominant and
serodiagnostic antigensgroups.Wealsofoundthat proteinswith
isoelectric points lower than 5 were 1.7- to 2.0-fold enriched in
serodominant and cross-reactive antigen groups, whereas, pro-
teinswithpI=9to14were0.6-and0.5-foldunderrepresentedin
these two groups.
Another potential feature that could account for protein
antigenicity is the level of in vivo expression; proteins expressed
at a high level in vivo would be expected more likely to be seen
by the immune system than proteins expressed at a low level. To
test this hypothesis, we compared the group of antigenic
B.melitensisproteinswithanexistingdatasetofexpressedprotein
peptide data from a very closely related species, B. abortus.
23,35,36
In this study, cytosolic proteins and cell envelope proteins from
B. abortus in the log phase of in vitro growth, were extracted and
subjected to LC Mass spectrometry (MS) analysis as described
in Materials and Methods. The number of diﬀerent peptides
identiﬁed for each protein was listed in Table S4 (Supporting
Information). Two-hundred forty proteins were exclusively ex-
pressed in the cytosol of B. abortus with 1 to12 detected peptides,
and 53 proteins exclusively expressed in the cell envelope of
B. abortus with 1 to 15 detected peptides, and 80 overlapping
proteins expressed in both conditions. Of these, 356 proteins
Table 1. Enrichment Analysis for B. abortus Homolog Proteins Expressed during in vitro Growth As Detected by Mass
Spectrometry
a
proteins serodominant serodiagnostic cross-reactive
B. abortus homologs expression on chip hits FoldEnrich p-value hits FoldEnrich p-value hits FoldEnrich p-value
Expressed and detected with at least 1 peptide 356 41 2.9 5.28E-11 20 5.2 1.87E-11 21 2.0 0.001
Expressed and detected with at least 2 peptides 175 23 3.3 2.04E-07 16 8.4 3.56E-12 7 1.4 0.353
Expressed and detected with at least 5 peptides 40 8 5.0 1.38E-04 7 16.2 1.30E-07 1 0.9 1.000
Expressed and detected with at least 7 peptides 16 4 6.2 3.07E-03 4 23.1 1.90E-05 0 0.0 1.000
Expressed and detected with at least 9 peptides 9 2 5.5 4.76E-02 2 20.5 3.91E-03 0 0.0 1.000
Not expressed 2690 81 0.8 5.28E-11 13 0.4 1.87E-11 68 0.9 0.001
Total ORFs 3046 122 33 89
aSigniﬁcant enrichment or underrepresentation for certain features are underlined and bold.4820 dx.doi.org/10.1021/pr200619r |J. Proteome Res. 2011, 10, 4813–4824
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were printed on our proteome chip. Not surprisingly, expression
was a signiﬁcant enriching feature with 5.2-fold enrichment
among serodiagnostic antigens (p-value 1.87   10
 11), and 2.9-
foldin serodominant antigens (p-value 5.28   10
 11) (Table 1).
Interestingly, the fold enrichment was directly proportional to
thenumberofpeptidesdetected(Figure5C).Therewas8.4-fold
enrichment of serodiagnostic antigens in proteins detected with
more than 1 peptide (p-value 3.56   10
 12), 16.2- fold in pro-
teins detected with 5 or more peptides (p-value 1.30   10
 7),
23.1- fold enrichment in proteins detected with 7 or more
peptides (p-value 1.90   10
 5), and 20.5-fold enrichment in
proteins detected with 9 or more peptides (p-value 3.91   10
 3).
Conversely, proteins that were not identiﬁed by MS were signif-
icantlyunderrepresentedat0.4-foldamongtheserodiagnosticand
0.8-fold among serodominant antigens. The data suggests that
protein expression level is an important factor contributing to
antigenicity of protein antigens. This was also supported by data
in other experimental systems from diﬀerent research groups.
55
There are a total of 10 enriching features that fall into 3
categories: (i) functionally annotated COGs U, M, N and O, (ii)
computationallypredictedfeatures(TMHMM=1,SignalP>0.7,
pSort Outermembrane, pSort Periplasmic, and pI < 5), and
(iii) MS evidence of expression. The Venn diagrams summarize
the number of enriched proteins found in each of these 3
categories, showing overlap among the proteins found in each
category(Figure6).Thereare338proteinsintheenrichedCOG
categories, 696 computationally predicted proteins, and 356
proteins that were positive by MS (Table 2). Accounting for
the overlap between categories, 1128 proteins in all enriched
categories represented 37% of the proteome. The microarray
results empirically identiﬁed 33 serodiagnostic antigens and 89
cross-reactive antigens. COGs accounted for 30% of the sero-
diagnostichits,thecomputationallypredictedfeaturesaccounted
for 61% of the hits, and MS positive proteins contained 61% of
the hits. All together the three categories account for 37% of the
proteome and include 91% of the serodiagnostic antigens. But
there is only 1 unique serodiagnostic COG antigen that is not
represented in either the computationally predicted or MS+
categories (BMEI1060, Table S1, Supporting Information). So
by combining the pool of computationally predicted and MS+
proteins representing 30% of the proteome, 88% of the sero-
diagnostic antigens can be predicted.
Table 2. Enrichment Summary for Antigens with Categorized Enriching Features
a
whole genome (3046 on chip) cross-reactive (89 total) serodiagnostic (33 total)
enriching features predicted % of total predicted % of total predicted % of total
COGs-U, M, N, O 338 11% 27 30% 10 30%
Computationally Predicted 696 23% 47 53% 20 61%
Mass Spectrometry Positive (MS+) 356 12% 21 24% 20 61%
COGs + Predicted 919 30% 60 67% 22 67%
COGs + Predicted + MS+ 1128 37% 69 78% 30 91%
Predicted + MS+ 925 30% 58 65% 29 88%
aEnrichingfeaturesareclassiﬁedintothreecategories:(1)COGs-UMNO,forproteinsassignedtooneormoreofthesefourCOGs;(2)Computational
predictions with enriching features, for proteins predicted to have one or more of the following features, i.e., TMHMM = 1, SignalP > 0.7, pSort
Outermembrane,pSortPeriplasmic,orpI<5;and(3)Proteinexpressionasdetectedbymassspectrometry.Numbersofoverlappingantigensfortwoor
three categories are shown in Figure 6.
Figure 6. Venn diagram of numbers of antigens with categorized enriching features. Enriching features are classiﬁed into three categories: (1) COGs-
UMNO,forproteinsassignedtooneormoreofthesefourCOGs;(2)Computationalpredictionswithenrichingfeatures,forproteinspredictedtohave
one or more of the following features, that is, TMHMM = 1, SignalP > 0.7, pSort Outermembrane, pSort Periplasmic, or pI < 5, and (3) Protein
expression as detected by peptide presence in Mass Spectrometry. Separately shown are numbers of antigens with enriching features, including all such
1128 antigens on chip, 99 serodominant, and 30 serodiagnostic antigens. Numbers of antigens having more than one category of enriching features are
also presented in the overlapping region of such categories.4821 dx.doi.org/10.1021/pr200619r |J. Proteome Res. 2011, 10, 4813–4824
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’DISCUSSION
Todaywithincreasingeﬃciency,accuracyandspeedweaccess
completed genome sequences from thousands of infectious micro-
organisms. However, systems- level studies to understand the
complete network of antibody responses have not been widely
performed. This work was motivated by the disturbing lack of a
detailed scientiﬁc understanding of the antibody responses to
infectiousdiseases.Wehavebeentakingasystemsbiologyapproach
to account for all of the antibodies that develop after exposure to
infectious microorganisms and to identify speciﬁca n t i b o d ys i g n a -
tures associated with each disease, in order to understand the
molecular basis for antigen selection by the immune system and
to predict serodiagnostic and vaccine antigens targets.
Thisstudyistheﬁrstfullproteome-wideserologicalanalysisof
B.melitensis. Our previous studyidentiﬁedaset ofserodiagnostic
antigensfromarandomlyselectedhalfoftheB.melitensisproteome.
However,animportantdiﬀerencebetweenthepresentstudyand
thispreviousreportisthatanalysisofthecompleteproteomenot
only has allowed us to delineate additional serodiagnostic antigens
but, more fundamentally, also provided the basis for a rigorous,
comprehensive and quantitative determination of basic biologi-
cal characteristics of the entire set of the serodominant antigens
on a genomic level.
The current standard serological screening assay, an aggluti-
nation test that uses tinted, killed bacteria as antigen (Rose
Bengal) is based primarily on identiﬁcation of antibodies to LPS
in patient serum. In the present microarray study, we conﬁrmed
LPS reactivity (with puriﬁed LPS spotted onto the microarray),
and identiﬁed novel protein antigens. The signature antigens
were validated using traditional Western blots. Although anti-
body responses against all 33 protein antigens used together can
predict disease with 92% accuracy, using the serological re-
sponses against the top 3 individual antigens together improves
accuracy to >98% for diagnosis of acute human brucellosis. One
limitation is that the humans studied here only had acute or
subacutebrucellosis-feverbutnotfocalorchronicdisease.Future
studiesareneededtoassesssuspectedcasesthatareagglutination
test negative, for example chronic neurobrucellosis or focal
disease such as orchitis or vertebral osteomyelitis.
Eleven of the 33 serodiagnostic antigens identiﬁed in this
studywere also identiﬁedon the pilot array
5 (TableS1, Support-
ing Information). Our ﬁndings are in good agreement with
publishedstudiesthatidentiﬁedwellcharacterized antigensfrom
other Brucella spp, including Bp26 (BMEI0536),
20,25,31,56 HtrA/
DegP (BMEI1330),
28 Omp16 (BMEI0340),
29 the chaperonin
GroELprotein(BMEII1048)andOmp10(BMEII0017).
21,57In
addition to the well characterized antigens, we also identiﬁed 21
novel serodiagnostic antigens on the current array, including top
antigen hypothetical protein BMEI0805. Two pyruvate dehy-
drogenase complex molecules and the associated acetyl CoA
hydrolase, which together form a large multimeric structure con-
sistingof 60 subunits, are also diﬀerentially recognized; this large
enzyme complex is found in most bacteria and is frequently a
target of immune recognition for other infections.
6,58
Protein microarrays enable enrichment analyses to identify
proteomic features that are enriched in the immunodominant
antigen set, and development of protein antigenicity prediction
tools based on enriched features. The prediction tools then can
be applied on a high-throughput scale to existing or new proteomes
toidentifykeyantigenicproteinsthatmayhaveserodiagnosticor
protectivecharacteristics.Enrichmentanalysisidentiﬁed10proteomic
features that are enriched in the serodiagnostic signature anti-
gens. The proteomic features fall into 3 categories: (i) COG
annotations, (ii) computationally predicted proteomic features,
and (iii) proteins with MS evidence of expression in viable
organisms. No single proteomic feature or category of features
is suﬃcient to identify all these signature antigens. Our data
suggests that cloning of 37% of genome with these enriching
features would reveal more than 90% of serodiagnostic antigens.
We have classiﬁed the reactive immunodominant antigens for
numerous agents and have consistently found these features
predict antigenicity.
6,7,10,59
These results describe the relationship between antigenicity
and in vivo expression of individual proteins. In our study, we
utilized the expression of proteins quantiﬁed by MS of a closely
related strain, B. abortus during in vitro growth. We found that
mass spec positive antigens were signiﬁcantly enriched among
serodiagnostic antigens but not among the cross- reactive anti-
gens. This validates the classiﬁcation of the serodiagnostic
antigens being derived from actively replicating organisms, and
validates the classiﬁcation of cross-reactive antigens being de-
rived from previous exposure to nonbrucellosis infections.
Although the number of peptides observed per protein has been
applied to estimating protein abundance,
60 62 we are aware that
massspectraofculturedorganismsmaynotreﬂecttheexpression
during infection in vivo. First, nutrients are not limiting in log
phase growth in vitro, whereas in vivo, Brucella is likely to be
within a nutrient-limited intracellular environment.
63 Second,
the MS method may not be particularly quantitative, especially
for membrane proteins. Our protein array technology is also
able to provide strong evidence of the comprehensive set of
proteinsexpressedinvivowithinamammalianhostbyB.melitensis,
by virtue of their exposure to the host immune system. The
expressionandabundanceofproteinsduringinvivogrowthmerits
furtherexaminationbyothernoveltechnologies,suchasmeasure-
mentoftranscriptabundancefromRNA-seq(“deepsequencing”)
technique.
64
The B. melitensis immunoproteome comprises 1464 antigens
that are signiﬁcantly reactive in at least one of the individuals in
this study. Only 122 serodominant antigens are signiﬁcantly
recognized by most of the individuals. Answers to questions of
why and how the immune system focuses on 4% of the potential
target antigens are not yet apparent from this work. One might
expect that an immune response against a larger collection of
antigens could result in a more eﬀective immune response attack
against the infectious agent. But antibody responses against
thousands of antigens from hundreds of clinical infections could
accumulate during a lifetime, leading to cross reactivity against
autologous antigens and autoimmune chaos. This could provide
evolutionaryselectionpressurefavoringamorefocusedresponse
to infection. The observation that dozens of organism- speciﬁc
antibody responses develop after B. melitensis infection is con-
sistent with similar observations from other infectious agents,
and has implications for subunit vaccine discovery and develop-
ment. Mimicking the natural response to infection could be
considered a viable strategy for vaccine development but most
subunit vaccines aim to derive protection from immunization
with only a single antigen. Attenuated or killed whole organism
vaccines produce an antibody reactivity proﬁle against dozens of
antigens more similar to natural infection.
6
This systematic genome scale analysis of human antibody
responses against B. melitensis proteins provides a top hit list of
antigens worthy of assessing for improved diagnostics, and4822 dx.doi.org/10.1021/pr200619r |J. Proteome Res. 2011, 10, 4813–4824
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furthermore, enables development of a predictive model of
proteomic features that determine whether a protein is antigenic
and produces antibodies that confer protection. This systems
biology approach provides an empirical basis for understanding
the breadth and speciﬁcity of the immune response to B. melitensis
and a new framework for comparing the humoral responses
against other organisms.
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